Search

Your search keyword '"Palakurthi, Sangeetha"' showing total 202 results
Start Over Author "Palakurthi, Sangeetha"
202 results on '"Palakurthi, Sangeetha"'

1. Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours

Author

Konstantinopoulos, Panagiotis A., Cheng, Su-Chun, Supko, Jeffrey G., Polak, Madeline, Wahner-Hendrickson, Andrea E., Ivy, S. Percy, Bowes, Brittany, Sawyer, Hannah, Basada, Patrice, Hayes, Martin, Curtis, Jennifer, Horowitz, Neil, Wright, Alexi A., Campos, Susana M., Ivanova, Elena V., Paweletz, Cloud P., Palakurthi, Sangeetha, Liu, Joyce F., D’Andrea, Alan D., Gokhale, Prafulla C., Chowdhury, Dipanjan, Matulonis, Ursula A., and Shapiro, Geoffrey I.

Published
2022
Full Text
View/download PDF

2. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial

Author

Konstantinopoulos, Panagiotis A, Barry, William T, Birrer, Michael, Westin, Shannon N, Cadoo, Karen A, Shapiro, Geoffrey I, Mayer, Erica L, O'Cearbhaill, Roisin E, Coleman, Robert L, Kochupurakkal, Bose, Whalen, Christin, Curtis, Jennifer, Farooq, Sarah, Luo, Weixiu, Eismann, Julia, Buss, Mary K, Aghajanian, Carol, Mills, Gordon B, Palakurthi, Sangeetha, Kirschmeier, Paul, Liu, Joyce, Cantley, Lewis C, Kaufmann, Scott H, Swisher, Elizabeth M, D'Andrea, Alan D, Winer, Eric, Wulf, Gerburg M, and Matulonis, Ursula A

Published
2019
Full Text
View/download PDF

3. A T cell receptor β chain–directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity

Author

Hsu, Jonathan, primary, Donahue, Renee N., additional, Katragadda, Madan, additional, Lowry, Jessica, additional, Huang, Wei, additional, Srinivasan, Karunya, additional, Guntas, Gurkan, additional, Tang, Jian, additional, Servattalab, Roya, additional, Moisan, Jacques, additional, Tsai, Yo-Ting, additional, Stoop, Allart, additional, Palakurthi, Sangeetha, additional, Chopra, Raj, additional, Liu, Ke, additional, Wherry, E. John, additional, Su, Zhen, additional, Gulley, James L., additional, Bayliffe, Andrew, additional, and Schlom, Jeffrey, additional

Published
2023
Full Text
View/download PDF

5. Data from The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity

Author

Palakurthi, Sangeetha, primary, Kuraguchi, Mari, primary, Zacharek, Sima J., primary, Zudaire, Enrique, primary, Huang, Wei, primary, Bonal, Dennis M., primary, Liu, Jeffrey, primary, Dhaneshwar, Abha, primary, DePeaux, Kristin, primary, Gowaski, Martha R., primary, Bailey, Dyane, primary, Regan, Samuel N., primary, Ivanova, Elena, primary, Ferrante, Catherine, primary, English, Jessie M., primary, Khosla, Aditya, primary, Beck, Andrew H., primary, Rytlewski, Julie A., primary, Sanders, Catherine, primary, Laquerre, Sylvie, primary, Bittinger, Mark A., primary, Kirschmeier, Paul T., primary, Packman, Kathryn, primary, Janne, Pasi A., primary, Moy, Christopher, primary, Wong, Kwok-Kin, primary, Verona, Raluca I., primary, and Lorenzi, Matthew V., primary

Published
2023
Full Text
View/download PDF

6. Supplementary Figure Legends, Tables and Methods from The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity

Author

Palakurthi, Sangeetha, primary, Kuraguchi, Mari, primary, Zacharek, Sima J., primary, Zudaire, Enrique, primary, Huang, Wei, primary, Bonal, Dennis M., primary, Liu, Jeffrey, primary, Dhaneshwar, Abha, primary, DePeaux, Kristin, primary, Gowaski, Martha R., primary, Bailey, Dyane, primary, Regan, Samuel N., primary, Ivanova, Elena, primary, Ferrante, Catherine, primary, English, Jessie M., primary, Khosla, Aditya, primary, Beck, Andrew H., primary, Rytlewski, Julie A., primary, Sanders, Catherine, primary, Laquerre, Sylvie, primary, Bittinger, Mark A., primary, Kirschmeier, Paul T., primary, Packman, Kathryn, primary, Janne, Pasi A., primary, Moy, Christopher, primary, Wong, Kwok-Kin, primary, Verona, Raluca I., primary, and Lorenzi, Matthew V., primary

Published
2023
Full Text
View/download PDF

7. Supplemental Figures 1-8 from The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity

Author

Palakurthi, Sangeetha, primary, Kuraguchi, Mari, primary, Zacharek, Sima J., primary, Zudaire, Enrique, primary, Huang, Wei, primary, Bonal, Dennis M., primary, Liu, Jeffrey, primary, Dhaneshwar, Abha, primary, DePeaux, Kristin, primary, Gowaski, Martha R., primary, Bailey, Dyane, primary, Regan, Samuel N., primary, Ivanova, Elena, primary, Ferrante, Catherine, primary, English, Jessie M., primary, Khosla, Aditya, primary, Beck, Andrew H., primary, Rytlewski, Julie A., primary, Sanders, Catherine, primary, Laquerre, Sylvie, primary, Bittinger, Mark A., primary, Kirschmeier, Paul T., primary, Packman, Kathryn, primary, Janne, Pasi A., primary, Moy, Christopher, primary, Wong, Kwok-Kin, primary, Verona, Raluca I., primary, and Lorenzi, Matthew V., primary

Published
2023
Full Text
View/download PDF

8. Data from CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

Author

Deng, Jiehui, primary, Wang, Eric S., primary, Jenkins, Russell W., primary, Li, Shuai, primary, Dries, Ruben, primary, Yates, Kathleen, primary, Chhabra, Sandeep, primary, Huang, Wei, primary, Liu, Hongye, primary, Aref, Amir R., primary, Ivanova, Elena, primary, Paweletz, Cloud P., primary, Bowden, Michaela, primary, Zhou, Chensheng W., primary, Herter-Sprie, Grit S., primary, Sorrentino, Jessica A., primary, Bisi, John E., primary, Lizotte, Patrick H., primary, Merlino, Ashley A., primary, Quinn, Max M., primary, Bufe, Lauren E., primary, Yang, Annan, primary, Zhang, Yanxi, primary, Zhang, Hua, primary, Gao, Peng, primary, Chen, Ting, primary, Cavanaugh, Megan E., primary, Rode, Amanda J., primary, Haines, Eric, primary, Roberts, Patrick J., primary, Strum, Jay C., primary, Richards, William G., primary, Lorch, Jochen H., primary, Parangi, Sareh, primary, Gunda, Viswanath, primary, Boland, Genevieve M., primary, Bueno, Raphael, primary, Palakurthi, Sangeetha, primary, Freeman, Gordon J., primary, Ritz, Jerome, primary, Haining, W. Nicholas, primary, Sharpless, Norman E., primary, Arthanari, Haribabu, primary, Shapiro, Geoffrey I., primary, Barbie, David A., primary, Gray, Nathanael S., primary, and Wong, Kwok-Kin, primary

Published
2023
Full Text
View/download PDF

9. Supplementary Figure S5 from Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness

Author

Iavarone, Claudia, primary, Zervantonakis, Ioannis K., primary, Selfors, Laura M., primary, Palakurthi, Sangeetha, primary, Liu, Joyce F., primary, Drapkin, Ronny, primary, Matulonis, Ursula A., primary, Hallberg, Dorothy, primary, Velculescu, Victor E., primary, Leverson, Joel D., primary, Sampath, Deepak, primary, Mills, Gordon B., primary, and Brugge, Joan S., primary

Published
2023
Full Text
View/download PDF

10. Data from Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

Author

Jenkins, Russell W., primary, Aref, Amir R., primary, Lizotte, Patrick H., primary, Ivanova, Elena, primary, Stinson, Susanna, primary, Zhou, Chensheng W., primary, Bowden, Michaela, primary, Deng, Jiehui, primary, Liu, Hongye, primary, Miao, Diana, primary, He, Meng Xiao, primary, Walker, William, primary, Zhang, Gao, primary, Tian, Tian, primary, Cheng, Chaoran, primary, Wei, Zhi, primary, Palakurthi, Sangeetha, primary, Bittinger, Mark, primary, Vitzthum, Hans, primary, Kim, Jong Wook, primary, Merlino, Ashley, primary, Quinn, Max, primary, Venkataramani, Chandrasekar, primary, Kaplan, Joshua A., primary, Portell, Andrew, primary, Gokhale, Prafulla C., primary, Phillips, Bart, primary, Smart, Alicia, primary, Rotem, Asaf, primary, Jones, Robert E., primary, Keogh, Lauren, primary, Anguiano, Maria, primary, Stapleton, Lance, primary, Jia, Zhiheng, primary, Barzily-Rokni, Michal, primary, Cañadas, Israel, primary, Thai, Tran C., primary, Hammond, Marc R., primary, Vlahos, Raven, primary, Wang, Eric S., primary, Zhang, Hua, primary, Li, Shuai, primary, Hanna, Glenn J., primary, Huang, Wei, primary, Hoang, Mai P., primary, Piris, Adriano, primary, Eliane, Jean-Pierre, primary, Stemmer-Rachamimov, Anat O., primary, Cameron, Lisa, primary, Su, Mei-Ju, primary, Shah, Parin, primary, Izar, Benjamin, primary, Thakuria, Manisha, primary, LeBoeuf, Nicole R., primary, Rabinowits, Guilherme, primary, Gunda, Viswanath, primary, Parangi, Sareh, primary, Cleary, James M., primary, Miller, Brian C., primary, Kitajima, Shunsuke, primary, Thummalapalli, Rohit, primary, Miao, Benchun, primary, Barbie, Thanh U., primary, Sivathanu, Vivek, primary, Wong, Joshua, primary, Richards, William G., primary, Bueno, Raphael, primary, Yoon, Charles H., primary, Miret, Juan, primary, Herlyn, Meenhard, primary, Garraway, Levi A., primary, Van Allen, Eliezer M., primary, Freeman, Gordon J., primary, Kirschmeier, Paul T., primary, Lorch, Jochen H., primary, Ott, Patrick A., primary, Hodi, F. Stephen, primary, Flaherty, Keith T., primary, Kamm, Roger D., primary, Boland, Genevieve M., primary, Wong, Kwok-Kin, primary, Dornan, David, primary, Paweletz, Cloud Peter, primary, and Barbie, David A., primary

Published
2023
Full Text
View/download PDF

11. Supp. Movie 3 from Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

Author

Jenkins, Russell W., primary, Aref, Amir R., primary, Lizotte, Patrick H., primary, Ivanova, Elena, primary, Stinson, Susanna, primary, Zhou, Chensheng W., primary, Bowden, Michaela, primary, Deng, Jiehui, primary, Liu, Hongye, primary, Miao, Diana, primary, He, Meng Xiao, primary, Walker, William, primary, Zhang, Gao, primary, Tian, Tian, primary, Cheng, Chaoran, primary, Wei, Zhi, primary, Palakurthi, Sangeetha, primary, Bittinger, Mark, primary, Vitzthum, Hans, primary, Kim, Jong Wook, primary, Merlino, Ashley, primary, Quinn, Max, primary, Venkataramani, Chandrasekar, primary, Kaplan, Joshua A., primary, Portell, Andrew, primary, Gokhale, Prafulla C., primary, Phillips, Bart, primary, Smart, Alicia, primary, Rotem, Asaf, primary, Jones, Robert E., primary, Keogh, Lauren, primary, Anguiano, Maria, primary, Stapleton, Lance, primary, Jia, Zhiheng, primary, Barzily-Rokni, Michal, primary, Cañadas, Israel, primary, Thai, Tran C., primary, Hammond, Marc R., primary, Vlahos, Raven, primary, Wang, Eric S., primary, Zhang, Hua, primary, Li, Shuai, primary, Hanna, Glenn J., primary, Huang, Wei, primary, Hoang, Mai P., primary, Piris, Adriano, primary, Eliane, Jean-Pierre, primary, Stemmer-Rachamimov, Anat O., primary, Cameron, Lisa, primary, Su, Mei-Ju, primary, Shah, Parin, primary, Izar, Benjamin, primary, Thakuria, Manisha, primary, LeBoeuf, Nicole R., primary, Rabinowits, Guilherme, primary, Gunda, Viswanath, primary, Parangi, Sareh, primary, Cleary, James M., primary, Miller, Brian C., primary, Kitajima, Shunsuke, primary, Thummalapalli, Rohit, primary, Miao, Benchun, primary, Barbie, Thanh U., primary, Sivathanu, Vivek, primary, Wong, Joshua, primary, Richards, William G., primary, Bueno, Raphael, primary, Yoon, Charles H., primary, Miret, Juan, primary, Herlyn, Meenhard, primary, Garraway, Levi A., primary, Van Allen, Eliezer M., primary, Freeman, Gordon J., primary, Kirschmeier, Paul T., primary, Lorch, Jochen H., primary, Ott, Patrick A., primary, Hodi, F. Stephen, primary, Flaherty, Keith T., primary, Kamm, Roger D., primary, Boland, Genevieve M., primary, Wong, Kwok-Kin, primary, Dornan, David, primary, Paweletz, Cloud Peter, primary, and Barbie, David A., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Data from CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

Author

Deng, Jiehui, primary, Wang, Eric S., primary, Jenkins, Russell W., primary, Li, Shuai, primary, Dries, Ruben, primary, Yates, Kathleen, primary, Chhabra, Sandeep, primary, Huang, Wei, primary, Liu, Hongye, primary, Aref, Amir R., primary, Ivanova, Elena, primary, Paweletz, Cloud P., primary, Bowden, Michaela, primary, Zhou, Chensheng W., primary, Herter-Sprie, Grit S., primary, Sorrentino, Jessica A., primary, Bisi, John E., primary, Lizotte, Patrick H., primary, Merlino, Ashley A., primary, Quinn, Max M., primary, Bufe, Lauren E., primary, Yang, Annan, primary, Zhang, Yanxi, primary, Zhang, Hua, primary, Gao, Peng, primary, Chen, Ting, primary, Cavanaugh, Megan E., primary, Rode, Amanda J., primary, Haines, Eric, primary, Roberts, Patrick J., primary, Strum, Jay C., primary, Richards, William G., primary, Lorch, Jochen H., primary, Parangi, Sareh, primary, Gunda, Viswanath, primary, Boland, Genevieve M., primary, Bueno, Raphael, primary, Palakurthi, Sangeetha, primary, Freeman, Gordon J., primary, Ritz, Jerome, primary, Haining, W. Nicholas, primary, Sharpless, Norman E., primary, Arthanari, Haribabu, primary, Shapiro, Geoffrey I., primary, Barbie, David A., primary, Gray, Nathanael S., primary, and Wong, Kwok-Kin, primary

Published
2023
Full Text
View/download PDF

13. Supp. Movie 1 from Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

Author

Jenkins, Russell W., primary, Aref, Amir R., primary, Lizotte, Patrick H., primary, Ivanova, Elena, primary, Stinson, Susanna, primary, Zhou, Chensheng W., primary, Bowden, Michaela, primary, Deng, Jiehui, primary, Liu, Hongye, primary, Miao, Diana, primary, He, Meng Xiao, primary, Walker, William, primary, Zhang, Gao, primary, Tian, Tian, primary, Cheng, Chaoran, primary, Wei, Zhi, primary, Palakurthi, Sangeetha, primary, Bittinger, Mark, primary, Vitzthum, Hans, primary, Kim, Jong Wook, primary, Merlino, Ashley, primary, Quinn, Max, primary, Venkataramani, Chandrasekar, primary, Kaplan, Joshua A., primary, Portell, Andrew, primary, Gokhale, Prafulla C., primary, Phillips, Bart, primary, Smart, Alicia, primary, Rotem, Asaf, primary, Jones, Robert E., primary, Keogh, Lauren, primary, Anguiano, Maria, primary, Stapleton, Lance, primary, Jia, Zhiheng, primary, Barzily-Rokni, Michal, primary, Cañadas, Israel, primary, Thai, Tran C., primary, Hammond, Marc R., primary, Vlahos, Raven, primary, Wang, Eric S., primary, Zhang, Hua, primary, Li, Shuai, primary, Hanna, Glenn J., primary, Huang, Wei, primary, Hoang, Mai P., primary, Piris, Adriano, primary, Eliane, Jean-Pierre, primary, Stemmer-Rachamimov, Anat O., primary, Cameron, Lisa, primary, Su, Mei-Ju, primary, Shah, Parin, primary, Izar, Benjamin, primary, Thakuria, Manisha, primary, LeBoeuf, Nicole R., primary, Rabinowits, Guilherme, primary, Gunda, Viswanath, primary, Parangi, Sareh, primary, Cleary, James M., primary, Miller, Brian C., primary, Kitajima, Shunsuke, primary, Thummalapalli, Rohit, primary, Miao, Benchun, primary, Barbie, Thanh U., primary, Sivathanu, Vivek, primary, Wong, Joshua, primary, Richards, William G., primary, Bueno, Raphael, primary, Yoon, Charles H., primary, Miret, Juan, primary, Herlyn, Meenhard, primary, Garraway, Levi A., primary, Van Allen, Eliezer M., primary, Freeman, Gordon J., primary, Kirschmeier, Paul T., primary, Lorch, Jochen H., primary, Ott, Patrick A., primary, Hodi, F. Stephen, primary, Flaherty, Keith T., primary, Kamm, Roger D., primary, Boland, Genevieve M., primary, Wong, Kwok-Kin, primary, Dornan, David, primary, Paweletz, Cloud Peter, primary, and Barbie, David A., primary

Published
2023
Full Text
View/download PDF

14. Table S3 from Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

Author

Jenkins, Russell W., primary, Aref, Amir R., primary, Lizotte, Patrick H., primary, Ivanova, Elena, primary, Stinson, Susanna, primary, Zhou, Chensheng W., primary, Bowden, Michaela, primary, Deng, Jiehui, primary, Liu, Hongye, primary, Miao, Diana, primary, He, Meng Xiao, primary, Walker, William, primary, Zhang, Gao, primary, Tian, Tian, primary, Cheng, Chaoran, primary, Wei, Zhi, primary, Palakurthi, Sangeetha, primary, Bittinger, Mark, primary, Vitzthum, Hans, primary, Kim, Jong Wook, primary, Merlino, Ashley, primary, Quinn, Max, primary, Venkataramani, Chandrasekar, primary, Kaplan, Joshua A., primary, Portell, Andrew, primary, Gokhale, Prafulla C., primary, Phillips, Bart, primary, Smart, Alicia, primary, Rotem, Asaf, primary, Jones, Robert E., primary, Keogh, Lauren, primary, Anguiano, Maria, primary, Stapleton, Lance, primary, Jia, Zhiheng, primary, Barzily-Rokni, Michal, primary, Cañadas, Israel, primary, Thai, Tran C., primary, Hammond, Marc R., primary, Vlahos, Raven, primary, Wang, Eric S., primary, Zhang, Hua, primary, Li, Shuai, primary, Hanna, Glenn J., primary, Huang, Wei, primary, Hoang, Mai P., primary, Piris, Adriano, primary, Eliane, Jean-Pierre, primary, Stemmer-Rachamimov, Anat O., primary, Cameron, Lisa, primary, Su, Mei-Ju, primary, Shah, Parin, primary, Izar, Benjamin, primary, Thakuria, Manisha, primary, LeBoeuf, Nicole R., primary, Rabinowits, Guilherme, primary, Gunda, Viswanath, primary, Parangi, Sareh, primary, Cleary, James M., primary, Miller, Brian C., primary, Kitajima, Shunsuke, primary, Thummalapalli, Rohit, primary, Miao, Benchun, primary, Barbie, Thanh U., primary, Sivathanu, Vivek, primary, Wong, Joshua, primary, Richards, William G., primary, Bueno, Raphael, primary, Yoon, Charles H., primary, Miret, Juan, primary, Herlyn, Meenhard, primary, Garraway, Levi A., primary, Van Allen, Eliezer M., primary, Freeman, Gordon J., primary, Kirschmeier, Paul T., primary, Lorch, Jochen H., primary, Ott, Patrick A., primary, Hodi, F. Stephen, primary, Flaherty, Keith T., primary, Kamm, Roger D., primary, Boland, Genevieve M., primary, Wong, Kwok-Kin, primary, Dornan, David, primary, Paweletz, Cloud Peter, primary, and Barbie, David A., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Data from Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

Author

Jenkins, Russell W., primary, Aref, Amir R., primary, Lizotte, Patrick H., primary, Ivanova, Elena, primary, Stinson, Susanna, primary, Zhou, Chensheng W., primary, Bowden, Michaela, primary, Deng, Jiehui, primary, Liu, Hongye, primary, Miao, Diana, primary, He, Meng Xiao, primary, Walker, William, primary, Zhang, Gao, primary, Tian, Tian, primary, Cheng, Chaoran, primary, Wei, Zhi, primary, Palakurthi, Sangeetha, primary, Bittinger, Mark, primary, Vitzthum, Hans, primary, Kim, Jong Wook, primary, Merlino, Ashley, primary, Quinn, Max, primary, Venkataramani, Chandrasekar, primary, Kaplan, Joshua A., primary, Portell, Andrew, primary, Gokhale, Prafulla C., primary, Phillips, Bart, primary, Smart, Alicia, primary, Rotem, Asaf, primary, Jones, Robert E., primary, Keogh, Lauren, primary, Anguiano, Maria, primary, Stapleton, Lance, primary, Jia, Zhiheng, primary, Barzily-Rokni, Michal, primary, Cañadas, Israel, primary, Thai, Tran C., primary, Hammond, Marc R., primary, Vlahos, Raven, primary, Wang, Eric S., primary, Zhang, Hua, primary, Li, Shuai, primary, Hanna, Glenn J., primary, Huang, Wei, primary, Hoang, Mai P., primary, Piris, Adriano, primary, Eliane, Jean-Pierre, primary, Stemmer-Rachamimov, Anat O., primary, Cameron, Lisa, primary, Su, Mei-Ju, primary, Shah, Parin, primary, Izar, Benjamin, primary, Thakuria, Manisha, primary, LeBoeuf, Nicole R., primary, Rabinowits, Guilherme, primary, Gunda, Viswanath, primary, Parangi, Sareh, primary, Cleary, James M., primary, Miller, Brian C., primary, Kitajima, Shunsuke, primary, Thummalapalli, Rohit, primary, Miao, Benchun, primary, Barbie, Thanh U., primary, Sivathanu, Vivek, primary, Wong, Joshua, primary, Richards, William G., primary, Bueno, Raphael, primary, Yoon, Charles H., primary, Miret, Juan, primary, Herlyn, Meenhard, primary, Garraway, Levi A., primary, Van Allen, Eliezer M., primary, Freeman, Gordon J., primary, Kirschmeier, Paul T., primary, Lorch, Jochen H., primary, Ott, Patrick A., primary, Hodi, F. Stephen, primary, Flaherty, Keith T., primary, Kamm, Roger D., primary, Boland, Genevieve M., primary, Wong, Kwok-Kin, primary, Dornan, David, primary, Paweletz, Cloud Peter, primary, and Barbie, David A., primary

Published
2023
Full Text
View/download PDF

16. Data from Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness

Author

Iavarone, Claudia, primary, Zervantonakis, Ioannis K., primary, Selfors, Laura M., primary, Palakurthi, Sangeetha, primary, Liu, Joyce F., primary, Drapkin, Ronny, primary, Matulonis, Ursula A., primary, Hallberg, Dorothy, primary, Velculescu, Victor E., primary, Leverson, Joel D., primary, Sampath, Deepak, primary, Mills, Gordon B., primary, and Brugge, Joan S., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Table 1 from Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness

Author

Iavarone, Claudia, primary, Zervantonakis, Ioannis K., primary, Selfors, Laura M., primary, Palakurthi, Sangeetha, primary, Liu, Joyce F., primary, Drapkin, Ronny, primary, Matulonis, Ursula A., primary, Hallberg, Dorothy, primary, Velculescu, Victor E., primary, Leverson, Joel D., primary, Sampath, Deepak, primary, Mills, Gordon B., primary, and Brugge, Joan S., primary

Published
2023
Full Text
View/download PDF

18. Supp. Movie 2 from Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

Author

Jenkins, Russell W., primary, Aref, Amir R., primary, Lizotte, Patrick H., primary, Ivanova, Elena, primary, Stinson, Susanna, primary, Zhou, Chensheng W., primary, Bowden, Michaela, primary, Deng, Jiehui, primary, Liu, Hongye, primary, Miao, Diana, primary, He, Meng Xiao, primary, Walker, William, primary, Zhang, Gao, primary, Tian, Tian, primary, Cheng, Chaoran, primary, Wei, Zhi, primary, Palakurthi, Sangeetha, primary, Bittinger, Mark, primary, Vitzthum, Hans, primary, Kim, Jong Wook, primary, Merlino, Ashley, primary, Quinn, Max, primary, Venkataramani, Chandrasekar, primary, Kaplan, Joshua A., primary, Portell, Andrew, primary, Gokhale, Prafulla C., primary, Phillips, Bart, primary, Smart, Alicia, primary, Rotem, Asaf, primary, Jones, Robert E., primary, Keogh, Lauren, primary, Anguiano, Maria, primary, Stapleton, Lance, primary, Jia, Zhiheng, primary, Barzily-Rokni, Michal, primary, Cañadas, Israel, primary, Thai, Tran C., primary, Hammond, Marc R., primary, Vlahos, Raven, primary, Wang, Eric S., primary, Zhang, Hua, primary, Li, Shuai, primary, Hanna, Glenn J., primary, Huang, Wei, primary, Hoang, Mai P., primary, Piris, Adriano, primary, Eliane, Jean-Pierre, primary, Stemmer-Rachamimov, Anat O., primary, Cameron, Lisa, primary, Su, Mei-Ju, primary, Shah, Parin, primary, Izar, Benjamin, primary, Thakuria, Manisha, primary, LeBoeuf, Nicole R., primary, Rabinowits, Guilherme, primary, Gunda, Viswanath, primary, Parangi, Sareh, primary, Cleary, James M., primary, Miller, Brian C., primary, Kitajima, Shunsuke, primary, Thummalapalli, Rohit, primary, Miao, Benchun, primary, Barbie, Thanh U., primary, Sivathanu, Vivek, primary, Wong, Joshua, primary, Richards, William G., primary, Bueno, Raphael, primary, Yoon, Charles H., primary, Miret, Juan, primary, Herlyn, Meenhard, primary, Garraway, Levi A., primary, Van Allen, Eliezer M., primary, Freeman, Gordon J., primary, Kirschmeier, Paul T., primary, Lorch, Jochen H., primary, Ott, Patrick A., primary, Hodi, F. Stephen, primary, Flaherty, Keith T., primary, Kamm, Roger D., primary, Boland, Genevieve M., primary, Wong, Kwok-Kin, primary, Dornan, David, primary, Paweletz, Cloud Peter, primary, and Barbie, David A., primary

Published
2023
Full Text
View/download PDF

20. Figure S3 from The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition

Author

Parmar, Kalindi, primary, Kochupurakkal, Bose S., primary, Lazaro, Jean-Bernard, primary, Wang, Zhigang C., primary, Palakurthi, Sangeetha, primary, Kirschmeier, Paul T., primary, Yang, Chunyu, primary, Sambel, Larissa A., primary, Färkkilä, Anniina, primary, Reznichenko, Elizaveta, primary, Reavis, Hunter D., primary, Dunn, Connor E., primary, Zou, Lee, primary, Do, Khanh T., primary, Konstantinopoulos, Panagiotis A., primary, Matulonis, Ursula A., primary, Liu, Joyce F., primary, D'Andrea, Alan D., primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

21. Suppl. Figure S3 from Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer

Author

Bahcall, Magda, primary, Awad, Mark M., primary, Sholl, Lynette M., primary, Wilson, Frederick H., primary, Xu, Man, primary, Wang, Stephen, primary, Palakurthi, Sangeetha, primary, Choi, Jihyun, primary, Ivanova, Elena V., primary, Leonardi, Giulia C., primary, Ulrich, Bryan C., primary, Paweletz, Cloud P., primary, Kirschmeier, Paul T., primary, Watanabe, Masayuki, primary, Baba, Hideo, primary, Nishino, Mizuki, primary, Nagy, Rebecca J., primary, Lanman, Richard B., primary, Capelletti, Marzia, primary, Chambers, Emily S., primary, Redig, Amanda J., primary, VanderLaan, Paul A., primary, Costa, Daniel B., primary, Imamura, Yu, primary, and Jänne, Pasi A., primary

Published
2023
Full Text
View/download PDF

22. Supplemental Table 2 from Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics

Author

Liu, Joyce F., primary, Palakurthi, Sangeetha, primary, Zeng, Qing, primary, Zhou, Shan, primary, Ivanova, Elena, primary, Huang, Wei, primary, Zervantonakis, Ioannis K., primary, Selfors, Laura M., primary, Shen, Yiping, primary, Pritchard, Colin C., primary, Zheng, Mei, primary, Adleff, Vilmos, primary, Papp, Eniko, primary, Piao, Huiying, primary, Novak, Marian, primary, Fotheringham, Susan, primary, Wulf, Gerburg M., primary, English, Jessie, primary, Kirschmeier, Paul T., primary, Velculescu, Victor E., primary, Paweletz, Cloud, primary, Mills, Gordon B., primary, Livingston, David M., primary, Brugge, Joan S., primary, Matulonis, Ursula A., primary, and Drapkin, Ronny, primary

Published
2023
Full Text
View/download PDF

23. Suppl. Table S1 from Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer

Author

Bahcall, Magda, primary, Awad, Mark M., primary, Sholl, Lynette M., primary, Wilson, Frederick H., primary, Xu, Man, primary, Wang, Stephen, primary, Palakurthi, Sangeetha, primary, Choi, Jihyun, primary, Ivanova, Elena V., primary, Leonardi, Giulia C., primary, Ulrich, Bryan C., primary, Paweletz, Cloud P., primary, Kirschmeier, Paul T., primary, Watanabe, Masayuki, primary, Baba, Hideo, primary, Nishino, Mizuki, primary, Nagy, Rebecca J., primary, Lanman, Richard B., primary, Capelletti, Marzia, primary, Chambers, Emily S., primary, Redig, Amanda J., primary, VanderLaan, Paul A., primary, Costa, Daniel B., primary, Imamura, Yu, primary, and Jänne, Pasi A., primary

Published
2023
Full Text
View/download PDF

24. Data from Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer

Author

Bahcall, Magda, primary, Awad, Mark M., primary, Sholl, Lynette M., primary, Wilson, Frederick H., primary, Xu, Man, primary, Wang, Stephen, primary, Palakurthi, Sangeetha, primary, Choi, Jihyun, primary, Ivanova, Elena V., primary, Leonardi, Giulia C., primary, Ulrich, Bryan C., primary, Paweletz, Cloud P., primary, Kirschmeier, Paul T., primary, Watanabe, Masayuki, primary, Baba, Hideo, primary, Nishino, Mizuki, primary, Nagy, Rebecca J., primary, Lanman, Richard B., primary, Capelletti, Marzia, primary, Chambers, Emily S., primary, Redig, Amanda J., primary, VanderLaan, Paul A., primary, Costa, Daniel B., primary, Imamura, Yu, primary, and Jänne, Pasi A., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Table S1 from The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition

Author

Parmar, Kalindi, primary, Kochupurakkal, Bose S., primary, Lazaro, Jean-Bernard, primary, Wang, Zhigang C., primary, Palakurthi, Sangeetha, primary, Kirschmeier, Paul T., primary, Yang, Chunyu, primary, Sambel, Larissa A., primary, Färkkilä, Anniina, primary, Reznichenko, Elizaveta, primary, Reavis, Hunter D., primary, Dunn, Connor E., primary, Zou, Lee, primary, Do, Khanh T., primary, Konstantinopoulos, Panagiotis A., primary, Matulonis, Ursula A., primary, Liu, Joyce F., primary, D'Andrea, Alan D., primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Methods from Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer

Author

Bahcall, Magda, primary, Awad, Mark M., primary, Sholl, Lynette M., primary, Wilson, Frederick H., primary, Xu, Man, primary, Wang, Stephen, primary, Palakurthi, Sangeetha, primary, Choi, Jihyun, primary, Ivanova, Elena V., primary, Leonardi, Giulia C., primary, Ulrich, Bryan C., primary, Paweletz, Cloud P., primary, Kirschmeier, Paul T., primary, Watanabe, Masayuki, primary, Baba, Hideo, primary, Nishino, Mizuki, primary, Nagy, Rebecca J., primary, Lanman, Richard B., primary, Capelletti, Marzia, primary, Chambers, Emily S., primary, Redig, Amanda J., primary, VanderLaan, Paul A., primary, Costa, Daniel B., primary, Imamura, Yu, primary, and Jänne, Pasi A., primary

Published
2023
Full Text
View/download PDF

27. Supplemental Tables 1, 3, and 6; Supplemental Figures 1-5 from Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics

Author

Liu, Joyce F., primary, Palakurthi, Sangeetha, primary, Zeng, Qing, primary, Zhou, Shan, primary, Ivanova, Elena, primary, Huang, Wei, primary, Zervantonakis, Ioannis K., primary, Selfors, Laura M., primary, Shen, Yiping, primary, Pritchard, Colin C., primary, Zheng, Mei, primary, Adleff, Vilmos, primary, Papp, Eniko, primary, Piao, Huiying, primary, Novak, Marian, primary, Fotheringham, Susan, primary, Wulf, Gerburg M., primary, English, Jessie, primary, Kirschmeier, Paul T., primary, Velculescu, Victor E., primary, Paweletz, Cloud, primary, Mills, Gordon B., primary, Livingston, David M., primary, Brugge, Joan S., primary, Matulonis, Ursula A., primary, and Drapkin, Ronny, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure Legends from The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition

Author

Parmar, Kalindi, primary, Kochupurakkal, Bose S., primary, Lazaro, Jean-Bernard, primary, Wang, Zhigang C., primary, Palakurthi, Sangeetha, primary, Kirschmeier, Paul T., primary, Yang, Chunyu, primary, Sambel, Larissa A., primary, Färkkilä, Anniina, primary, Reznichenko, Elizaveta, primary, Reavis, Hunter D., primary, Dunn, Connor E., primary, Zou, Lee, primary, Do, Khanh T., primary, Konstantinopoulos, Panagiotis A., primary, Matulonis, Ursula A., primary, Liu, Joyce F., primary, D'Andrea, Alan D., primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

29. Supplemental Table 5 from Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics

Author

Liu, Joyce F., primary, Palakurthi, Sangeetha, primary, Zeng, Qing, primary, Zhou, Shan, primary, Ivanova, Elena, primary, Huang, Wei, primary, Zervantonakis, Ioannis K., primary, Selfors, Laura M., primary, Shen, Yiping, primary, Pritchard, Colin C., primary, Zheng, Mei, primary, Adleff, Vilmos, primary, Papp, Eniko, primary, Piao, Huiying, primary, Novak, Marian, primary, Fotheringham, Susan, primary, Wulf, Gerburg M., primary, English, Jessie, primary, Kirschmeier, Paul T., primary, Velculescu, Victor E., primary, Paweletz, Cloud, primary, Mills, Gordon B., primary, Livingston, David M., primary, Brugge, Joan S., primary, Matulonis, Ursula A., primary, and Drapkin, Ronny, primary

Published
2023
Full Text
View/download PDF

30. A phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients with hepatocellular carcinoma and other solid tumor types known for association with the MYC oncogene (MYCHELANGELO I).

Author

Rodriguez-Rivera, Ildefonso I, primary, Wu, Ting-Hui, additional, Ciotti, Rachel, additional, Senapedis, William, additional, Sullivan, Kaitlyn, additional, Gao, Jeff Z, additional, Palakurthi, Sangeetha, additional, McCauley, Thomas, additional, and Moore, Yan, additional

Published
2023
Full Text
View/download PDF

31. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia

Author

Keeton, Erika K., McEachern, Kristen, Dillman, Keith S., Palakurthi, Sangeetha, Cao, Yichen, Grondine, Michael R., Kaur, Surinder, Wang, Suping, Chen, Yuching, Wu, Allan, Shen, Minhui, Gibbons, Francis D., Lamb, Michelle L., Zheng, Xiaolan, Stone, Richard M., DeAngelo, Daniel J., Platanias, Leonidas C., Dakin, Les A., Chen, Huawei, Lyne, Paul D., and Huszar, Dennis

Published
2014
Full Text
View/download PDF

32. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors

Author

Jia, Yong, Yun, Cai-Hong, Park, Eunyoung, Ercan, Dalia, Manuia, Mari, Juarez, Jose, Xu, Chunxiao, Rhee, Kevin, Chen, Ting, Zhang, Haikuo, Palakurthi, Sangeetha, Jang, Jaebong, Lelais, Gerald, DiDonato, Michael, Bursulaya, Badry, Michellys, Pierre-Yves, Epple, Robert, Marsilje, Thomas H., McNeill, Matthew, Lu, Wenshuo, Harris, Jennifer, Bender, Steven, Wong, Kwok-Kin, Janne, Pasi A., and Eck, Michael J.

Subjects
Allosteric proteins -- Physiological aspects, Lung cancer, Non-small cell -- Care and treatment, Suppression, Genetic -- Care and treatment, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

The epidermal growth factor receptor (EGFR)-directed tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib and afatinib are approved treatments for non-small cell lung cancers harbouring activating mutations in the EGFR kinase (1,2), [...]

Published
2016

34. Erratum: Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2

Author

Zhang, Haikuo, Brainson, Christine Fillmore, Koyama, Shohei, Redig, Amanda J., Chen, Ting, Li, Shuai, Gupta, Manav, Garcia-de-Alba, Carolina, Paschini, Margherita, Herter-Sprie, Grit S., Lu, Gang, Zhang, Xin, Marsh, Bryan P, Tuminello, Stephanie J., Xu, Chunxiao, Chen, Zhao, Wang, Xiaoen, Akbay, Esra A., Zheng, Mei, Palakurthi, Sangeetha, Sholl, Lynette M., Rustgi, Anil K., Kwiatkowski, David J., Alan Diehl, J., Bass, Adam J., Sharpless, Norman E., Dranoff, Glenn, Hammerman, Peter S., Ji, Hongbin, Bardeesy, Nabeel, Saur, Dieter, Watanabe, Hideo, Kim, Carla F., and Wong, Kwok-Kin

Published
2017
Full Text
View/download PDF

35. Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours

Author

Konstantinopoulos, Panagiotis A., primary, Cheng, Su-Chun, additional, Supko, Jeffrey G., additional, Polak, Madeline, additional, Wahner-Hendrickson, Andrea E., additional, Ivy, S. Percy, additional, Bowes, Brittany, additional, Sawyer, Hannah, additional, Basada, Patrice, additional, Hayes, Martin, additional, Curtis, Jennifer, additional, Horowitz, Neil, additional, Wright, Alexi A., additional, Campos, Susana M., additional, Ivanova, Elena V., additional, Paweletz, Cloud P., additional, Palakurthi, Sangeetha, additional, Liu, Joyce F., additional, D’Andrea, Alan D., additional, Gokhale, Prafulla C., additional, Chowdhury, Dipanjan, additional, Matulonis, Ursula A., additional, and Shapiro, Geoffrey I., additional

Published
2021
Full Text
View/download PDF

36. Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR -mutant lung cancer

Author

Eser, Pınar Özden, primary, Paranal, Raymond M., additional, Son, Jieun, additional, Ivanova, Elena, additional, Kuang, Yanan, additional, Haikala, Heidi M., additional, To, Ciric, additional, Okoro, Jeffrey J., additional, Dholakia, Kshiti H., additional, Choi, Jihyun, additional, Eum, Yoonji, additional, Ogino, Atsuko, additional, Missios, Pavlos, additional, Ercan, Dalia, additional, Xu, Man, additional, Poitras, Michael J., additional, Wang, Stephen, additional, Ngo, Kenneth, additional, Dills, Michael, additional, Yanagita, Masahiko, additional, Lopez, Timothy, additional, Lin, Mika, additional, Tsai, Jeanelle, additional, Floch, Nicolas, additional, Chambers, Emily S., additional, Heng, Jennifer, additional, Anjum, Rana, additional, Santucci, Alison D., additional, Michael, Kesi, additional, Schuller, Alwin G., additional, Cross, Darren, additional, Smith, Paul D., additional, Oxnard, Geoffrey R., additional, Barbie, David A., additional, Sholl, Lynette M., additional, Bahcall, Magda, additional, Palakurthi, Sangeetha, additional, Gokhale, Prafulla C., additional, Paweletz, Cloud P., additional, Daley, George Q., additional, and Jänne, Pasi A., additional

Published
2021
Full Text
View/download PDF

37. Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations

Author

Ogino, Atsuko, primary, Choi, Jihyun, additional, Lin, Mika, additional, Wilkens, Margaret K., additional, Calles, Antonio, additional, Xu, Man, additional, Adeni, Anika E., additional, Chambers, Emily S., additional, Capelletti, Marzia, additional, Butaney, Mohit, additional, Gray, Nathanael S., additional, Gokhale, Prafulla C., additional, Palakurthi, Sangeetha, additional, Kirschmeier, Paul, additional, Oxnard, Geoffrey R., additional, Sholl, Lynette M., additional, and Jänne, Pasi A., additional

Published
2020
Full Text
View/download PDF

38. Depletion of intracellular Ca2+ stores, phosphorylation of eIF2alpha, and sustained inhibition of translation initiation mediate the anticancer effects of clotrimazole

Author

Aktas, Huseyin, Fluckiger, Rudolf, Acosta, Juan A., Savage, Joyce M., Palakurthi, Sangeetha S., and Halperin, Jose A.

Subjects
Cell interaction -- Research, Phosphorylation -- Research, Genetic translation -- Research, Antineoplastic agents -- Research, Clotrimazole -- Research, Growth factors -- Research, Cell division -- Research, Eukaryotic cells -- Research, Science and technology
Abstract

Regulation of translation initiation plays a critical role in the control of cell growth and division in eukaryotic cells. Translation of many growth regulatory proteins including cyclins depends critically on translation initiation factors because their mRNAs are translated inefficiently. We report that clotrimazole, a potent antiproliferative agent both in vitro and in vivo, inhibits cell growth by interfering with translation initiation. In particular, clotrimazole causes a sustained depletion of intracellular [Ca.sup.2+] stores, which results in activation of PKR, phosphorylation of elF2[Alpha], and thereby in inhibition of protein synthesis at the level of translation initiation. Consequently, clotrimazole preferentially decreases the expression of the growth promoting proteins cyclin A, E and D1, resulting in inhibition of cyclindependent kinase activity and blockage of cell cycle in [G.sub.1].

Published
1998

39. The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition

Author

Parmar, Kalindi, primary, Kochupurakkal, Bose S., additional, Lazaro, Jean-Bernard, additional, Wang, Zhigang C., additional, Palakurthi, Sangeetha, additional, Kirschmeier, Paul T., additional, Yang, Chunyu, additional, Sambel, Larissa A., additional, Färkkilä, Anniina, additional, Reznichenko, Elizaveta, additional, Reavis, Hunter D., additional, Dunn, Connor E., additional, Zou, Lee, additional, Do, Khanh T., additional, Konstantinopoulos, Panagiotis A., additional, Matulonis, Ursula A., additional, Liu, Joyce F., additional, D'Andrea, Alan D., additional, and Shapiro, Geoffrey I., additional

Published
2019
Full Text
View/download PDF

40. The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity

Author

Palakurthi, Sangeetha, primary, Kuraguchi, Mari, additional, Zacharek, Sima J., additional, Zudaire, Enrique, additional, Huang, Wei, additional, Bonal, Dennis M., additional, Liu, Jeffrey, additional, Dhaneshwar, Abha, additional, DePeaux, Kristin, additional, Gowaski, Martha R., additional, Bailey, Dyane, additional, Regan, Samuel N., additional, Ivanova, Elena, additional, Ferrante, Catherine, additional, English, Jessie M., additional, Khosla, Aditya, additional, Beck, Andrew H., additional, Rytlewski, Julie A., additional, Sanders, Catherine, additional, Laquerre, Sylvie, additional, Bittinger, Mark A., additional, Kirschmeier, Paul T., additional, Packman, Kathryn, additional, Janne, Pasi A., additional, Moy, Christopher, additional, Wong, Kwok-Kin, additional, Verona, Raluca I., additional, and Lorenzi, Matthew V., additional

Published
2019
Full Text
View/download PDF

41. Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness

Author

Iavarone, Claudia, primary, Zervantonakis, Ioannis K., additional, Selfors, Laura M., additional, Palakurthi, Sangeetha, additional, Liu, Joyce F., additional, Drapkin, Ronny, additional, Matulonis, Ursula A., additional, Hallberg, Dorothy, additional, Velculescu, Victor E., additional, Leverson, Joel D., additional, Sampath, Deepak, additional, Mills, Gordon B., additional, and Brugge, Joan S., additional

Published
2019
Full Text
View/download PDF

42. Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations.

Author

Ogino, Atsuko, Choi, Jihyun, Lin, Mika, Wilkens, Margaret K., Calles, Antonio, Xu, Man, Adeni, Anika E., Chambers, Emily S., Capelletti, Marzia, Butaney, Mohit, Gray, Nathanael S., Gokhale, Prafulla C., Palakurthi, Sangeetha, Kirschmeier, Paul, Oxnard, Geoffrey R., Sholl, Lynette M., and Jänne, Pasi A.

Abstract

Small‐cell lung cancer (SCLC) occurs infrequently in never/former light smokers. We sought to study this rare clinical subset through next‐generation sequencing (NGS) and by characterizing a representative patient‐derived model. We performed targeted NGS, as well as comprehensive pathological evaluation, in 11 never/former light smokers with clinically diagnosed SCLC. We established a patient‐derived model from one such patient (DFCI168) harboring an NRASQ61K mutation and characterized the sensitivity of this model to MEK and TORC1/2 inhibitors. Despite the clinical diagnosis of SCLC, the majority (8/11) of cases were either of nonpulmonary origin or of mixed histology and included atypical carcinoid (n = 1), mixed non‐small‐cell lung carcinoma and SCLC (n = 4), unspecified poorly differentiated carcinoma (n = 1), or small‐cell carcinoma from different origins (n = 2). RB1 and TP53 mutations were found in four and five cases, respectively. Predicted driver mutations were detected in EGFR (n = 2), NRAS (n = 1), KRAS (n = 1), BRCA1 (n = 1), and ATM (n = 1), and one case harbored a TMPRSS2‐ERG fusion. DFCI168 (NRASQ61K) exhibited marked sensitivity to MEK inhibitors in vitro and in vivo. The combination of MEK and mTORC1/2 inhibitors synergized to prevent compensatory mTOR activation, resulting in prolonged growth inhibition in this model and in three other NRAS mutant lung cancer cell lines. SCLC in never/former light smokers is rare and is potentially a distinct disease entity comprised of oncogenic driver mutation‐harboring carcinomas morphologically and/or clinically mimicking SCLC. Comprehensive pathologic review integrated with genomic profiling is critical in refining the diagnosis and in identifying potential therapeutic options. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

43. Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer

Author

Bahcall, Magda, primary, Awad, Mark M., additional, Sholl, Lynette M., additional, Wilson, Frederick H., additional, Xu, Man, additional, Wang, Stephen, additional, Palakurthi, Sangeetha, additional, Choi, Jihyun, additional, Ivanova, Elena V., additional, Leonardi, Giulia C., additional, Ulrich, Bryan C., additional, Paweletz, Cloud P., additional, Kirschmeier, Paul T., additional, Watanabe, Masayuki, additional, Baba, Hideo, additional, Nishino, Mizuki, additional, Nagy, Rebecca J., additional, Lanman, Richard B., additional, Capelletti, Marzia, additional, Chambers, Emily S., additional, Redig, Amanda J., additional, VanderLaan, Paul A., additional, Costa, Daniel B., additional, Imamura, Yu, additional, and Jänne, Pasi A., additional

Published
2018
Full Text
View/download PDF

44. Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13

Author

Zeng, Mei, primary, Kwiatkowski, Nicholas P, additional, Zhang, Tinghu, additional, Nabet, Behnam, additional, Xu, Mousheng, additional, Liang, Yanke, additional, Quan, Chunshan, additional, Wang, Jinhua, additional, Hao, Mingfeng, additional, Palakurthi, Sangeetha, additional, Zhou, Shan, additional, Zeng, Qing, additional, Kirschmeier, Paul T, additional, Meghani, Khyati, additional, Leggett, Alan L, additional, Qi, Jun, additional, Shapiro, Geoffrey I, additional, Liu, Joyce F, additional, Matulonis, Ursula A, additional, Lin, Charles Y, additional, Konstantinopoulos, Panagiotis A, additional, and Gray, Nathanael S, additional

Published
2018
Full Text
View/download PDF

45. Author response: Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13

Author

Zeng, Mei, primary, Kwiatkowski, Nicholas P, additional, Zhang, Tinghu, additional, Nabet, Behnam, additional, Xu, Mousheng, additional, Liang, Yanke, additional, Quan, Chunshan, additional, Wang, Jinhua, additional, Hao, Mingfeng, additional, Palakurthi, Sangeetha, additional, Zhou, Shan, additional, Zeng, Qing, additional, Kirschmeier, Paul T, additional, Meghani, Khyati, additional, Leggett, Alan L, additional, Qi, Jun, additional, Shapiro, Geoffrey I, additional, Liu, Joyce F, additional, Matulonis, Ursula A, additional, Lin, Charles Y, additional, Konstantinopoulos, Panagiotis A, additional, and Gray, Nathanael S, additional

Published
2018
Full Text
View/download PDF

46. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

Author

Jenkins, Russell W., primary, Aref, Amir R., additional, Lizotte, Patrick H., additional, Ivanova, Elena, additional, Stinson, Susanna, additional, Zhou, Chensheng W., additional, Bowden, Michaela, additional, Deng, Jiehui, additional, Liu, Hongye, additional, Miao, Diana, additional, He, Meng Xiao, additional, Walker, William, additional, Zhang, Gao, additional, Tian, Tian, additional, Cheng, Chaoran, additional, Wei, Zhi, additional, Palakurthi, Sangeetha, additional, Bittinger, Mark, additional, Vitzthum, Hans, additional, Kim, Jong Wook, additional, Merlino, Ashley, additional, Quinn, Max, additional, Venkataramani, Chandrasekar, additional, Kaplan, Joshua A., additional, Portell, Andrew, additional, Gokhale, Prafulla C., additional, Phillips, Bart, additional, Smart, Alicia, additional, Rotem, Asaf, additional, Jones, Robert E., additional, Keogh, Lauren, additional, Anguiano, Maria, additional, Stapleton, Lance, additional, Jia, Zhiheng, additional, Barzily-Rokni, Michal, additional, Cañadas, Israel, additional, Thai, Tran C., additional, Hammond, Marc R., additional, Vlahos, Raven, additional, Wang, Eric S., additional, Zhang, Hua, additional, Li, Shuai, additional, Hanna, Glenn J., additional, Huang, Wei, additional, Hoang, Mai P., additional, Piris, Adriano, additional, Eliane, Jean-Pierre, additional, Stemmer-Rachamimov, Anat O., additional, Cameron, Lisa, additional, Su, Mei-Ju, additional, Shah, Parin, additional, Izar, Benjamin, additional, Thakuria, Manisha, additional, LeBoeuf, Nicole R., additional, Rabinowits, Guilherme, additional, Gunda, Viswanath, additional, Parangi, Sareh, additional, Cleary, James M., additional, Miller, Brian C., additional, Kitajima, Shunsuke, additional, Thummalapalli, Rohit, additional, Miao, Benchun, additional, Barbie, Thanh U., additional, Sivathanu, Vivek, additional, Wong, Joshua, additional, Richards, William G., additional, Bueno, Raphael, additional, Yoon, Charles H., additional, Miret, Juan, additional, Herlyn, Meenhard, additional, Garraway, Levi A., additional, Van Allen, Eliezer M., additional, Freeman, Gordon J., additional, Kirschmeier, Paul T., additional, Lorch, Jochen H., additional, Ott, Patrick A., additional, Hodi, F. Stephen, additional, Flaherty, Keith T., additional, Kamm, Roger D., additional, Boland, Genevieve M., additional, Wong, Kwok-Kin, additional, Dornan, David, additional, Paweletz, Cloud Peter, additional, and Barbie, David A., additional

Published
2018
Full Text
View/download PDF

47. CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

Author

Deng, Jiehui, primary, Wang, Eric S., additional, Jenkins, Russell W., additional, Li, Shuai, additional, Dries, Ruben, additional, Yates, Kathleen, additional, Chhabra, Sandeep, additional, Huang, Wei, additional, Liu, Hongye, additional, Aref, Amir R., additional, Ivanova, Elena, additional, Paweletz, Cloud P., additional, Bowden, Michaela, additional, Zhou, Chensheng W., additional, Herter-Sprie, Grit S., additional, Sorrentino, Jessica A., additional, Bisi, John E., additional, Lizotte, Patrick H., additional, Merlino, Ashley A., additional, Quinn, Max M., additional, Bufe, Lauren E., additional, Yang, Annan, additional, Zhang, Yanxi, additional, Zhang, Hua, additional, Gao, Peng, additional, Chen, Ting, additional, Cavanaugh, Megan E., additional, Rode, Amanda J., additional, Haines, Eric, additional, Roberts, Patrick J., additional, Strum, Jay C., additional, Richards, William G., additional, Lorch, Jochen H., additional, Parangi, Sareh, additional, Gunda, Viswanath, additional, Boland, Genevieve M., additional, Bueno, Raphael, additional, Palakurthi, Sangeetha, additional, Freeman, Gordon J., additional, Ritz, Jerome, additional, Haining, W. Nicholas, additional, Sharpless, Norman E., additional, Arthanari, Haribabu, additional, Shapiro, Geoffrey I., additional, Barbie, David A., additional, Gray, Nathanael S., additional, and Wong, Kwok-Kin, additional

Published
2018
Full Text
View/download PDF

48. Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response

Author

Zervantonakis, Ioannis K., primary, Iavarone, Claudia, additional, Chen, Hsing-Yu, additional, Selfors, Laura M., additional, Palakurthi, Sangeetha, additional, Liu, Joyce F., additional, Drapkin, Ronny, additional, Matulonis, Ursula, additional, Leverson, Joel D., additional, Sampath, Deepak, additional, Mills, Gordon B., additional, and Brugge, Joan S., additional

Published
2017
Full Text
View/download PDF

49. Abstract 2796: Development of a RAD51-based assay for determining homologous recombination proficiency and PARP inhibitor sensitivity

Author

Kochupurakkal, Bose S., primary, Parmar, Kalindi, additional, Lazaro, Jean-Bernard, additional, Unitt, Christine, additional, Zeng, Qing, additional, Reavis, Hunter, additional, Ganesa, Chirag, additional, Zhou, Shan, additional, Liu, Joyce, additional, Palakurthi, Sangeetha, additional, Strickland, Kyle, additional, Howitt, Brooke, additional, Konstantinopoulos, Panagiotis, additional, Kirschmeier, Paul, additional, Geradts, Joseph, additional, Drapkin, Ronny, additional, Matulonis, Ursula, additional, D'Andrea, Alan, additional, and Shapiro, Geoffrey, additional

Published
2017
Full Text
View/download PDF

50. Abstract 4033: Combined MEK and BCL-2/XL inhibition as a potential drug combination for the treatment of high-grade serous ovarian cancer

Author

Iavarone, Claudia, primary, Zervantonakis, Ioannis, additional, Selfors, Laura M., additional, Palakurthi, Sangeetha, additional, Liu, Joyce F., additional, Matulonis, Ursula A., additional, Drapkin, Ronny I., additional, Mills, Gordon B., additional, Leverson, Joel D., additional, Sampath, Deepak, additional, and Brugge, Joan S., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results